Quantcast

Latest HER2/neu Stories

2014-08-20 08:27:31

MUMBAI, August 20, 2014 /PRNewswire/ -- Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody. GBR 1302 was discovered and developed by the Glenmark Biologics Research Centre located in La Chaux-de-Fonds, Switzerland. GBR 1302 is based on Glenmark's innovative BEAT antibody...

2014-08-12 16:27:36

DALLAS, Aug. 12, 2014 /PRNewswire/ -- ProPath®, a leader in pathology services and an advocate for advancements in healthcare, reinforces commitment to quality and efficiency through partnership with Dako, an Agilent Technologies Company. ProPath recently performed a head-to-head comparison study focusing on the accuracy and speed of two FDA-approved FISH (Fluorescence in situ hybridization) probe sets targeting the HER2 gene. Both kits are designed to detect amplification of the...

Researchers Discover New Route For Ovarian Cancer Spread
2014-07-15 03:14:42

University of Texas M. D. Anderson Cancer Center HER3-positive circulating tumor cells home in on omentum; new target to thwart metastasis Circulating tumor cells spread ovarian cancer through the bloodstream, homing in on a sheath of abdominal fatty tissue where it can grow and metastasize to other organs, scientists at The University of Texas MD Anderson Cancer Center report in Cancer Cell. "This completely new way of thinking about ovarian cancer metastasis provides new potential...

2014-07-02 16:24:20

ROCKVILLE, Md., July 2, 2014 /PRNewswire/ -- A collaborative study between OncoPlex Diagnostics, Vall d´Hebron Institute of Oncology (VHIO), and Memorial Sloan Kettering Cancer Center, with support from the BBVA Foundation, defined for the first time a quantitative HER2 protein level measured by mass spectrometry is associated with longer disease free and overall survival in patients receiving anti-HER2 treatment. Results of the study were presented during the ASCO 2014 Annual...

2014-06-26 08:27:43

- Trial will measure investigational compound's efficacy and safety in patients with HER2-negative breast cancer, associated with BRCA 1, BRCA 2 mutations NORTH CHICAGO, Ill., June 26, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the initiation of a Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), when added to carboplatin and paclitaxel, two chemotherapeutic medicines, in patients with advanced breast...

2014-06-17 16:25:41

NEW YORK, June 17, 2014 /PRNewswire/ -- According to GLOBOCAN 2012, breast cancer was the second most commonly diagnosed form of cancer in 2012 with 1.7 million new cases, and accounting for nearly 12% of all new cancer cases. Since the 2008 estimates, breast cancer incidence has increased by more than 20% while mortality has increased by 14%. With approximately 522,000 deaths in 2012, breast cancer is now the most common cause of cancer death among women. Furthermore, it is...

2014-06-16 08:29:23

DUBLIN, June 16, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/bqwbck/companion) has announced the addition of the "Companion Diagnostics Market (2nd Edition), 2014 - 2024" [http://www.researchandmarkets.com/research/bqwbck/companion ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The Companion Diagnostics Market (2nd Edition), 2014 - 2024' report provides an extensive study of the...

2014-06-03 23:08:44

ResearchMoz.us include new market research report "Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs" to its huge collection of research reports. Albany, NY (PRWEB) June 03, 2014 "Breast Cancer Therapeutics in Major Developed Markets to 2020 – Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs", which provides in-depth analysis of breast...

2014-06-02 16:26:24

OAKLAND, Calif., June 2, 2014 /PRNewswire/ -- Patients with specific HER2+ breast cancer tumors have a low risk of the cancer recurring five years after diagnosis, even without chemotherapy or treatment with a common antibody, according to a Kaiser Permanente study published in the Journal of Clinical Oncology. http://photos.prnewswire.com/prnvar/20130718/SF49717LOGO Researchers reviewed 16,975 cases of breast cancer diagnosed in Kaiser Permanente patients between 2000 and 2006....

2014-05-27 08:28:53

WALTHAM, Mass., May 27, 2014 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., today announced that clinical trial data on entinostat will be presented in two posters during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 30 - June 3, 2014, in Chicago. The first poster, titled "Phase 2 study investigating the safety, efficacy, and surrogate biomarkers of response to 5-azacitidine (5-AZA) and entinostat in advanced breast cancer," is being...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related